On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO's NAV by c $550m (c 63%). The deal brings the prospects of increased liquidity in RTWBIO's shares and a more efficient cost base, and potential for a higher RTWBIO valuation. Arix's shareholders would receive new RTWBIO shares at an implied c 46% premium to the level before Arix announced a strategic review. Meanwhile, RTWBIO's management team anticipates that the deal would be single-digit accretive to the company's NAV per share at completion.Den vollständigen Artikel lesen ...